Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. [electronic resource]
Producer: 20130214Description: 3319-27 p. digitalISSN:- 1879-0852
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Chromones -- administration & dosage
- Dose-Response Relationship, Drug
- Female
- Gastrointestinal Diseases -- chemically induced
- Hematologic Diseases -- chemically induced
- Humans
- Hypokalemia -- chemically induced
- Infusions, Intravenous
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Maximum Tolerated Dose
- Mechanistic Target of Rapamycin Complex 1
- Middle Aged
- Molecular Targeted Therapy
- Multiprotein Complexes
- Neoplasm Proteins -- antagonists & inhibitors
- Neoplasms -- drug therapy
- Oligopeptides -- administration & dosage
- Phosphoinositide-3 Kinase Inhibitors
- Prodrugs -- administration & dosage
- Protein Kinase Inhibitors -- administration & dosage
- Proteins -- antagonists & inhibitors
- Salvage Therapy
- TOR Serine-Threonine Kinases
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.